Ranbaxy Laboratories has received approval from the US Food and Drug Administration (FDA) to manufacture and market Doxycycline tablets 50mg, 75mg and 100mg in the US market.According to a release issued by Ranbaxy to the BSE today, the office of generic drugs, FDA has determined Ranbaxy's formulations to be bioequivalent and have the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical.'The annualized sale for Adoxa were $ 57.2 million of Doxycycline market which achieved sales of $ 62.70 million', the release added.
